LeonaBio, Inc. SEC filings LONA
LeonaBio, Inc. has 469 filings in SEC EDGAR's recent list, going back to Oct 3, 2014. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 11, 2026 | — |
| DEF 14A | Proxy statement | May 11, 2026 | Jun 22, 2026 |
| DEF 14A | Proxy statement | Feb 23, 2026 | Mar 18, 2026 |
| PRE 14A | Preliminary proxy statement | Feb 4, 2026 | Mar 18, 2026 |
| DEFA14A | Additional proxy material | Apr 14, 2025 | — |
| DEF 14A | Proxy statement | Apr 14, 2025 | May 29, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2025 | May 29, 2025 |
| DEFA14A | Additional proxy material | Apr 9, 2024 | — |
| DEF 14A | Proxy statement | Apr 9, 2024 | May 23, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 28, 2024 | May 23, 2024 |
| DEFA14A | Additional proxy material | Apr 5, 2023 | — |
| DEF 14A | Proxy statement | Apr 5, 2023 | May 18, 2023 |
| DEFA14A | Additional proxy material | May 17, 2022 | — |
| DEFA14A | Additional proxy material | May 17, 2022 | — |
| DEFA14A | Additional proxy material | May 11, 2022 | — |
| DEFA14A | Additional proxy material | May 9, 2022 | — |
| DEFA14A | Additional proxy material | May 5, 2022 | — |
| DEFA14A | Additional proxy material | May 5, 2022 | — |
| DEFA14A | Additional proxy material | May 5, 2022 | — |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEFA14A | Additional proxy material | Apr 20, 2022 | — |
| DEFA14A | Additional proxy material | Apr 11, 2022 | — |
| DEFA14A | Additional proxy material | Apr 11, 2022 | — |
| DEFA14A | Additional proxy material | Apr 5, 2022 | — |
| DEFA14A | Additional proxy material | Mar 30, 2022 | — |
| DEFA14A | Additional proxy material | Mar 28, 2022 | — |
| DEFA14A | Additional proxy material | Apr 16, 2021 | — |
| DEF 14A | Proxy statement | Apr 16, 2021 | May 27, 2021 |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LONA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1620463
- Former names
- Athira Pharma, Inc. (until Jan 8, 2026); M3 Biotechnology, Inc. (until Jan 23, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.